Literature DB >> 29050516

Human Bone Marrow Mesenchymal Stromal Cell-Derived Osteoblasts Promote the Expansion of Hematopoietic Progenitors Through Beta-Catenin and Notch Signaling Pathways.

Matthew Michalicka1, Gavin Boisjoli1, Suria Jahan1,2, Owen Hovey1,2, Emily Doxtator1, Ahmad Abu-Khader1, Roya Pasha1, Nicolas Pineault1,2.   

Abstract

Coculture of hematopoietic stem cells (HSC) with primary stromal cells from HSC niches supports the maintenance and expansion of HSC and progenitors ex vivo. However, a major drawback is the availability of primary human samples for research and clinical applications. We investigated the use of in vitro derived osteoblasts as a new source of feeder cells and characterized the molecular pathways that mediate their growth-promoting activities. First, we compared the growth and differentiation modulating activities of mesenchymal stromal cells (MSC)-derived osteoblasts (M-OST) with those of their undifferentiated precursor on umbilical cord blood (UCB) progenitors. Feeder-free cultures were also included as baseline control. Cell growth and expansion of hematopoietic progenitors were significantly enhanced by both feeder cell types. However, progenitor cell growth was considerably greater with M-OST. Coculture also promoted the maintenance of immature CD34+ progenitor subsets and modulated in a positive fashion the expression of several homing-related cell surface receptors, in a feeder-specific fashion. Serial transplantation experiments revealed that M-OST coculture supported the maintenance of long-term lympho-myeloid reconstituting HSC that provided engraftment levels that were generally superior to those from MSC cocultures. Mechanistically, we found that coculture with M-OST was associated with enhanced beta-catenin (β-Cat) activity in UCB cells and that abrogation of β-Cat/T-cell factor activity blunted the growth-promoting activity of the M-OST coculture. Conversely, Notch inhibition reduced UCB cell expansion, but to a much lesser extent. In conclusion, this study demonstrates that M-OST are excellent feeder cells for HSC and progenitors, and it identifies key molecular pathways that are responsible for the growth-enhancing activities of osteoblasts on UCB progenitors.

Entities:  

Keywords:  Notch; Wnt; beta-catenin; cord blood; hematopoietic stem and progenitors; osteoblasts

Mesh:

Substances:

Year:  2017        PMID: 29050516     DOI: 10.1089/scd.2017.0133

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  5 in total

Review 1.  Contextual Regulation of Skeletal Physiology by Notch Signaling.

Authors:  Daniel W Youngstrom; Kurt D Hankenson
Journal:  Curr Osteoporos Rep       Date:  2019-08       Impact factor: 5.096

2.  Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Lidan Zhu; Jia Liu; Peiyan Kong; Shichun Gao; Lu Wang; Huanfeng Liu; Cheng Zhang; Li Gao; Yimei Feng; Ting Chen; Lei Gao; Xi Zhang
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

Review 3.  Endothelial cells produce angiocrine factors to regulate bone and cartilage via versatile mechanisms.

Authors:  Sipin Zhu; Samuel Bennett; Vincent Kuek; Chuan Xiang; Huazi Xu; Vicki Rosen; Jiake Xu
Journal:  Theranostics       Date:  2020-05-01       Impact factor: 11.556

4.  Arterial endothelium creates a permissive niche for expansion of human cord blood hematopoietic stem and progenitor cells.

Authors:  Huilin Li; Haiyun Pei; Sihan Wang; Bowen Zhang; Zeng Fan; Yiming Liu; Xiaoyan Xie; Zhou Yang; Lei Xu; Yali Jia; Yun Bai; Yi Han; Lin Chen; Lijuan He; Xue Nan; Wen Yue; Xuetao Pei
Journal:  Stem Cell Res Ther       Date:  2020-08-14       Impact factor: 6.832

5.  TNFSF15 facilitates human umbilical cord blood haematopoietic stem cell expansion by activating Notch signal pathway.

Authors:  Yahui Ding; Shan Gao; Jian Shen; Tairan Bai; Ming Yang; Shiqi Xu; Yingdai Gao; Zhisong Zhang; Luyuan Li
Journal:  J Cell Mol Med       Date:  2020-09-10       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.